Teva Pharmaceutical Industries Limited
TEVA
NYSE7.33
Teva Pharmaceutical Industries Limited
NYSE:TEVA
RECENT
PRICE
7.33
P/E
RATIO
-4.90
(PEG:0.01)
P/E RATIO
RELATIVE
TO S&P
-0.20
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.19 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 06/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Fiscal year
12.25
2.54
1.65
0.39
14.21
0.81
3.27
0.50
15.94
2.29
3.04
0.61
17.99
3.72
3.82
0.75
20.58
3.10
3.46
0.90
23.30
2.25
3.98
0.98
23.93
1.49
2.60
1.28
23.77
3.58
4.92
1.36
22.98
1.86
5.58
1.35
22.94
0.34
4.53
1.63
22.03
(16.01)
2.59
1.14
18.47
(2.11)
1.76
0.02
15.48
(0.92)
0.20
0.05
15.21
(3.64)
0.58
- -
14.41
0.38
0.21
- -
13.45
(2.12)
0.94
- -
13.43
(1.49)
0.87
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.71
17.87
0.87
20.90
0.82
22.04
0.79
24.49
1.18
24.94
1.27
26.11
1.21
26.58
1.09
27.33
0.90
34.82
0.94
34.91
0.86
17.09
0.64
14.40
0.48
12.81
0.53
9.16
0.51
9.33
0.49
7.83
0.48
7.72
CAPEX per share
Book Value per share
768
780
872
896
890
872
849
853
855
955
1,016
1,021
1,091
1,095
1,102
1,110
1,112
Comm.Shares outs.(m)
15.9
0.9
1.0%
55.4
2.6
1.1%
21.1
0.3
1.3%
14.8
0.7
1.4%
14.7
0.9
2.0%
18.5
1.2
2.3%
26.1
1.5
3.3%
14.4
0.8
2.6%
33.1
1.7
2.2%
148.0
6.7
3.2%
(1.6)
(0.1)
4.3%
(9.9)
(0.4)
0.1%
(12.6)
(0.5)
0.4%
(2.9)
(0.1)
- -
26.7
0.9
- -
(4.1)
(0.2)
- -
(4.9)
(0.2)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/23 | Q1)
Total liabilities
$34,844 m.
Total assets
$43,456 m.
Long-term debt
$20,013 m.
Cash and equiv.
$2,143 m.
Goodwill $17,799 m.
Retained earnings $(13,086) m.
Common stock 1,115 m. shares
Market Capitalisation
$8,213 m. (as of 11/6/23)
20,317
10.9%
20,314
8.1%
20,272
19.5%
19,652
17.1%
21,903
9.8%
22,385
(78.1)%
18,854
(8.7)%
16,887
(2.6)%
16,658
(21.4)%
15,879
10.8%
14,925
(14.1)%
14,926
14.1%
Revenue (m)
Operating margin
1,708
1,963
1,642
1,269
1,508
3,055
1,308
1,588
1,524
329
2,112
(16,265)
1,842
(2,150)
1,722
(999)
1,557
(3,990)
1,330
417
1,308
(2,353)
985
(1,663)
Depreciation (m)
Net profit (m)
(7.5)%
9.7%
(3.4)%
6.2%
16.2%
15.1%
27.0%
8.1%
63.2%
1.5%
10.5%
(72.7)%
7.5%
(11.4)%
22.0%
(5.9)%
3.8%
(24.0)%
32.1%
2.6%
20.8%
(15.8)%
37.1%
(10.8)%
Income tax rate
Net profit margin
3,467
11,712
22,768
1,755
10,387
22,565
2,107
8,566
23,313
5,393
8,383
29,769
(1,558)
32,524
33,337
(2,539)
28,829
17,359
(528)
26,700
14,707
(210)
24,997
13,972
(159)
23,210
10,026
1,546
22,033
10,278
582
19,452
8,691
1,090
20,013
8,612
Working capital (m)
Long-term debt (m)
Equity (m)
6.2%
4.3%
8.6%
4.5%
3.2%
5.6%
9.7%
8.5%
13.1%
4.4%
4.6%
5.3%
0.7%
1.5%
1.0%
(30.2)%
(25.0)%
(93.7)%
(2.9)%
(2.4)%
(14.6)%
(0.7)%
(0.7)%
(7.2)%
(8.4)%
(6.4)%
(39.8)%
2.9%
3.3%
4.1%
(7.3)%
(6.8)%
(27.1)%
4.0%
4.9%
(19.3)%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
2,177
2,165
2,801
Receivables
4,581
4,529
3,696
Inventory
4,403
3,818
3,833
Other
1,844
2,061
1,721
Current assets
13,005
12,573
12,051
Acc. Payable
1,756
1,686
1,887
Debt due
3,188
1,426
2,109
Other
8,220
7,915
7,473
Current liab.
13,164
11,027
11,469
55.2%
58.1%
13.1%
71.9%
62.0%
39.4%
27.7%
(35.6)%
(401.0)%
28.4%
107.1%
- -
100.9%
- -
105.2%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Teva Pharmaceutical Industries Limited (IL) started trading on February 1, 2013 (cik: 0000818686), operates in the Healthcare sector (Drug Manufacturers—Specialty & Generic industry), has 34,004 full-time employees, and is led by Mr. Richard D. Francis. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
-5.62%
-3.10%
Cash flow
94.26%
44.52%
Earnings
-132.21%
-627.33%
Dividends
- -
- -
Book value
-11.54%
-7.38%
Insider trading
Type
Shares
Date
Stark David Matthew
Sale
16,491
03/06/23
Stark David Matthew
Sale
49,475
03/07/23
Drape Eric
Sale
1,566
03/06/23
Drape Eric
Sale
4,699
03/07/23
Dethlefs Sven
Sale
19,355
03/06/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2021
3,982
3,910
3,886
4,100
15,878
2022
3,661
3,786
3,595
3,884
14,926
2023
3,661
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2021
0.07
0.19
0.26
(0.14)
0.39
2022
(0.88)
(0.23)
0.05
(1.13)
-2.19
2023
(0.18)
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
06/09/2023
Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend It
The Wall Street Journal - Read more...
11/21/2022
Teva Pharmaceutical Names Richard Francis as CEO
The Wall Street Journal - Read more...
10/14/2022
FDA Warns of Adderall Shortage Months After Patients Raised Concerns
The Wall Street Journal - Read more...
04/18/2022
J&J Settles With West Virginia in Opioid Suit for $99 Million
The Wall Street Journal - Read more...
12/31/2021
Teva Found Liable for Fueling Opioid Addiction in New York
The Wall Street Journal - Read more...